Azafaros to Present at J.P. Morgan’s 43rd Annual Healthcare Conference

Contributed by: Business Wire

Logo

Tags

Biotechnology

Pharmaceutical

Alternative Medicine

Health

FDA

Genetics

Clinical Trials

Other Health

Azafaros

More Like This

Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 2025

Azafaros granted important regulatory designations and clearance by European authorities for global Phase 3 studies, to be initiated in 2025

Azafaros announces positive topline Phase 2 study data with nizubaglustat in GM2 gangliosidosis and Niemann-Pick disease type C

Positive Niemann-Pick disease type C (NPC) and GM2 gangliosidosis data from nizubaglustat Phase 2 RAINBOW study conducted by Azafaros presented at major metabolic disease conference

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Areteia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025

Sobi to present new data at ASH 2023 Annual Meeting

Areteia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024